Evaluation of allergenicity of partially hydrolyzed soy formula and oral immunotherapy using the formula in children with soybean allergy

Not Applicable

• Conditions: food allergy

• Registration Number: JPRN-UMIN000030059
• Lead Sponsor: Aichi Children's Health and Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-11-22
• Study Completion: 2020-12-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Not provided

Exclusion Criteria

patients during oral immunotherapy for other food antigen. patients with severe comorbidity. patients with uncontrollable asthma or atopic dermatitis. patients who have developed anaphylaxis by soy allergen within one year before the oral food challenge. patients whom the doctor asses ineligible.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The threshold dose of soy milk and partially hydrolyzed soy formula in the patient with soybean allergy

Secondary Outcome Measures

Name	Time	Method
Efficacy and safety at 6 months of oral immunotherapy using partially hydrolyzed soy formula. Change of the basophil activation by oral immunotherapy using partially hydrolyzed soy formula. IgE-immunoblotting and ELISA using the serum of the patients soybeans allegy.